COL18A1 and cervical carcinoma: Rh-endostatin is a recombinant human vascular Rh-endostatinthelial inhibitor drug developed in China, which can inhibit angiogenesis through pan-targeting, and numerous studies have confirmed that Rh-endostatin can inhibit the growth of tumor cells and enhance the effectiveness of malignant tumor intervention.22-24 Therefore, the present study was a retrospective analysis of the interventional utility of Rh-endostatin combined with concurrent radiotherapy based on the cervical cancer population.